Medscape

Oral PCSK9 Inhibitor Provides LDL Reductions Comparable to the Injectables

NEW ORLEANS — Like the injectable therapies that came before, an oral once-daily PCSK9 inhibitor appears to generate profound reductions in LDL cholesterol (LDL-C), new data show, a result that ...
News Medical

New data supports earlier use of evolocumab in high-risk diabetes

Adding the PCSK9 inhibitor evolocumab to a high-intensity, cholesterol-lowering regimen reduced the risk of a first major cardiovascular event among adults with atherosclerotic cardiovascular disease ...
Medscape

In Global Trial, PCSK9 Inhibitor Provides Major Protection Against First CV Event

NEW ORLEANS — The first global randomized trial of the PCSK9 inhibitor evolocumab for the prevention of a primary major adverse cardiovascular event (MACE) found a relative reduction in risk similar ...
Medical Xpress

PCSK9 inhibitor lowers risk of first heart attack and stroke in high-risk adults

Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug evolocumab to patients' treatment significantly reduced the risk of major ...
KRDO

Experimental daily pill may lower cholesterol in patients who don’t see enough benefit with statins alone, study finds

(CNN) — For some people with high cholesterol, making lifestyle changes and taking routine statin medications may not be sufficient to help them reach their target cholesterol levels. For these ...
WRAL

Experimental daily pill may lower cholesterol in patients who don’t see enough benefit with statins alone, study finds

One group received evolocumab injections under the skin every two weeks while the other group received injections of a placebo every two weeks. The data showed that, after an average of 4.6 years, ...